We recently published a list of 10 Stocks Skyrocketing Today. In this article, we are going to take a look at where Viking ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity.

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

Viking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and manufacturing organization (CDMO), for both the oral and subcutaneous (SC ...

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

Shares of NASDAQ:VKTX opened at $26.52 on Tuesday. Viking Therapeutics has a 12-month low of $24.41 and a 12-month high of $89.10. The business has a 50 day moving average of $32.88 and a two ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...